We previously conducted a phase I clinical study using autologous tumor lysate-pulsed, monocyte-derived, mature DC vaccinations combined with low-dose IL-2 in patients with stage IV malignant melanoma, which showed that the treatment was safe [14]. Here, IL2 is linked to neoplasm.